Boston Scientific announced FDA 510(k) clearance for the Asurys Fluid Management System, designed to provide irrigation and distention during endoscopic urologic procedures, including ureteroscopies. Ureteroscopy is a common… read more.
Boston Scientific announced positive 12-month primary endpoint results from the second phase of the ADVANTAGE AF clinical trial evaluating the use of the Farapulse Pulsed Field Ablation (PFA)… read more.
Boston Scientific Corporation (announced data supporting the use of the FARAPULSE Pulsed Field Ablation (PFA) System during a late-breaking science session at AF Symposium 2025. Currently, the FARAPULSE… read more.
Boston Scientific Corporation announced positive three-year primary endpoint results from the OPTION global clinical trial of the Watchman FLX Left Atrial Appendage Closure (LAAC) Device. Key findings from… read more.
Boston Scientific Corporation announced it has received FDA approval for the Agent Drug-Coated Balloon (DCB), which is indicated to treat coronary in-stent restenosis (ISR) in patients with coronary… read more.
Boston Scientific Corporation announced that the FDA has approved an expanded indication of the WaveWriter SCS Systems for the treatment of chronic low back and leg pain in… read more.
Boston Scientific Corporation announced it has received FDA approval for the Farapulse Pulsed Field Ablation (PFA) System. The Farapulse PFA System is indicated for the isolation of pulmonary… read more.
Boston Scientific Corporation announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only FDA -cleared Intracept Intraosseous Nerve Ablation System, a therapy… read more.
Boston Scientific Corporation announced it has received approval for the latest-generation Watchman FLX Pro Left Atrial Appendage Closure (LAAC) Device. Designed to further advance the procedural performance and… read more.
Boston Scientific Corporation announced it has received FDA approval for the POLARx Cryoablation System.The new system, which is indicated for the treatment of patients with paroxysmal atrial fibrillation… read more.
– Primary results of the FROZEN-AF IDE trial with the POLARx Cryoablation System : Results from the global, prospective, non-randomized, single-arm FROZEN-AF IDE study of the POLARx Cryoablation… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
